Anika Therapeutics, Inc. (NASDAQ:ANIK) Short Interest Update

Anika Therapeutics, Inc. (NASDAQ:ANIK - Get Free Report) was the target of a significant increase in short interest during the month of April. As of April 15th, there was short interest totalling 811,100 shares, an increase of 5.3% from the March 31st total of 770,400 shares. Based on an average trading volume of 81,800 shares, the short-interest ratio is currently 9.9 days. Approximately 5.7% of the shares of the company are short sold.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Trexquant Investment LP bought a new position in shares of Anika Therapeutics during the third quarter valued at $944,000. GSA Capital Partners LLP bought a new position in shares of Anika Therapeutics during the third quarter valued at $962,000. Acadian Asset Management LLC lifted its holdings in shares of Anika Therapeutics by 184.5% during the third quarter. Acadian Asset Management LLC now owns 336,058 shares of the biotechnology company's stock valued at $6,255,000 after acquiring an additional 217,915 shares during the period. Hsbc Holdings PLC bought a new position in shares of Anika Therapeutics during the third quarter valued at $209,000. Finally, Capital Management Corp VA lifted its holdings in shares of Anika Therapeutics by 322.1% during the fourth quarter. Capital Management Corp VA now owns 355,534 shares of the biotechnology company's stock valued at $8,056,000 after acquiring an additional 271,309 shares during the period. 91.53% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the stock. StockNews.com upgraded shares of Anika Therapeutics from a "hold" rating to a "buy" rating in a research note on Thursday, March 14th. Stephens restated an "equal weight" rating and issued a $22.00 price objective on shares of Anika Therapeutics in a research note on Thursday, March 14th. Finally, Barrington Research raised their target price on Anika Therapeutics from $29.00 to $37.00 and gave the stock an "outperform" rating in a research report on Thursday, March 14th.

Anika Therapeutics Trading Up 2.3 %

ANIK stock traded up $0.60 during midday trading on Wednesday, hitting $26.49. The stock had a trading volume of 71,391 shares, compared to its average volume of 78,111. The firm has a market capitalization of $392.85 million, a price-to-earnings ratio of -4.69, a P/E/G ratio of 2.32 and a beta of 0.76. Anika Therapeutics has a 52 week low of $16.54 and a 52 week high of $28.13. The stock has a 50-day simple moving average of $25.56 and a 200 day simple moving average of $23.24.

Anika Therapeutics (NASDAQ:ANIK - Get Free Report) last issued its earnings results on Wednesday, March 13th. The biotechnology company reported $0.05 EPS for the quarter, topping the consensus estimate of ($0.15) by $0.20. The firm had revenue of $42.97 million during the quarter, compared to analysts' expectations of $41.51 million. Anika Therapeutics had a negative return on equity of 2.10% and a negative net margin of 49.60%. On average, equities analysts forecast that Anika Therapeutics will post 1.12 EPS for the current year.

About Anika Therapeutics

Anika Therapeutics, Inc, a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally.